Theravance Biopharma TBPH Amortization And Accretion Income
Amortization And Accretion Income at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept tbph:AmortizationAndAccretionIncome.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's amortization and accretion income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's amortization and accretion income?
- Theravance Biopharma (TBPH) reported amortization and accretion income of $602K in Q1 2026.
- How has Theravance Biopharma's amortization and accretion income changed year-over-year?
- Theravance Biopharma's amortization and accretion income increased by 84.1% year-over-year, from $327K to $602K.
- What is the long-term trend for Theravance Biopharma's amortization and accretion income?
- Over 3 years (2022 to 2025), Theravance Biopharma's amortization and accretion income has grown at a 60.8% compound annual growth rate (CAGR), from $681K to $2.83M.
- What does amortization and accretion income mean?
- This represents non-cash income recognized from the amortization of premiums or the accretion of discounts on financial assets or liabilities. It reflects the periodic adjustment of carrying values for long-term financial instruments toward their maturity value. Investors monitor this to distinguish between core operational cash flows and non-cash accounting adjustments related to financial holdings.